Pharmacogenomics

Effects of CYP2C19 genetic polymorphism on the pharmacokinetics of tolperisone in healthy subjects

Fri, 2022-12-23 06:00

Arch Pharm Res. 2022 Dec 23. doi: 10.1007/s12272-022-01423-0. Online ahead of print.

ABSTRACT

Tolperisone hydrochloride is a centrally-acting muscle relaxant used for relieving spasticities of neurological origin and muscle spasms associated with painful locomotor diseases. It is metabolized to the inactive metabolite mainly by CYP2D6 and, to a lesser extent, by CYP2C19 and CYP1A2. In our previous study, the pharmacokinetics of tolperisone was significantly affected by the genetic polymorphism of CYP2D6, but the wide interindividual variation of tolperisone pharmacokinetics was not explained by genetic polymorphism of CYP2D6 alone. Thus, we studied the effects of CYP2C19 genetic polymorphism on tolperisone pharmacokinetics. Eighty-one subjects with different CYP2C19 genotypes received a single oral dose of 150 mg tolperisone with 240 mL of water, and blood samples were collected up to 12 h after dosing. The plasma concentration of tolperisone was measured by a liquid chromatography-tandem mass spectrometry system. The CYP2C19PM group had significantly higher Cmax and lower CL/F values than the CYP2C19EM and CYP2C19IM groups. The AUCinf of the CYP2C19PM group was 2.86-fold and 3.00-fold higher than the CYP2C19EM and CYP2C19IM groups, respectively. In conclusion, the genetic polymorphism of CYP2C19 significantly affected tolperisone pharmacokinetics.

PMID:36564599 | DOI:10.1007/s12272-022-01423-0

Categories: Literature Watch

circPVT1 and PVT1/AKT3 show a role in cell proliferation, apoptosis, and tumor subtype-definition in Small Cell Lung Cancer

Fri, 2022-12-23 06:00

Genes Chromosomes Cancer. 2022 Dec 22. doi: 10.1002/gcc.23121. Online ahead of print.

NO ABSTRACT

PMID:36562080 | DOI:10.1002/gcc.23121

Categories: Literature Watch

MAP3K1 rs889312 polymorphism and cancer prognosis: A systematic review and meta-analysis

Fri, 2022-12-23 06:00

Cancer Rep (Hoboken). 2022 Dec 22:e1773. doi: 10.1002/cnr2.1773. Online ahead of print.

NO ABSTRACT

PMID:36560873 | DOI:10.1002/cnr2.1773

Categories: Literature Watch

Pharmacogenetic Dose Modeling Based on CYP2C19 Allelic Phenotypes

Fri, 2022-12-23 06:00

Pharmaceutics. 2022 Dec 16;14(12):2833. doi: 10.3390/pharmaceutics14122833.

NO ABSTRACT

PMID:36559326 | DOI:10.3390/pharmaceutics14122833

Categories: Literature Watch

In Vitro Cytopathogenic Activities of <em>Acanthamoeba</em> T3 and T4 Genotypes on HeLa Cell Monolayer

Fri, 2022-12-23 06:00

Pathogens. 2022 Dec 5;11(12):1474. doi: 10.3390/pathogens11121474.

NO ABSTRACT

PMID:36558808 | DOI:10.3390/pathogens11121474

Categories: Literature Watch

Impact of COVID-19 Pandemic on Disease Control Status and Quality of Life of Patients with Acromegaly

Fri, 2022-12-23 06:00

Medicina (Kaunas). 2022 Nov 23;58(12):1711. doi: 10.3390/medicina58121711.

NO ABSTRACT

PMID:36556914 | DOI:10.3390/medicina58121711

Categories: Literature Watch

The Transition from Cancer "omics" to "epi-omics" through Next- and Third-Generation Sequencing

Fri, 2022-12-23 06:00

Life (Basel). 2022 Dec 2;12(12):2010. doi: 10.3390/life12122010.

NO ABSTRACT

PMID:36556377 | DOI:10.3390/life12122010

Categories: Literature Watch

Patients' Perspectives of Factors That Influence Pharmacogenetic Testing Uptake: Enhancing Patient Counseling and Results Dissemination

Fri, 2022-12-23 06:00

J Pers Med. 2022 Dec 11;12(12):2046. doi: 10.3390/jpm12122046.

NO ABSTRACT

PMID:36556266 | DOI:10.3390/jpm12122046

Categories: Literature Watch

Physicians' Knowledge, Attitude, and Experience of Pharmacogenomic Testing in China

Fri, 2022-12-23 06:00

J Pers Med. 2022 Dec 7;12(12):2021. doi: 10.3390/jpm12122021.

NO ABSTRACT

PMID:36556242 | DOI:10.3390/jpm12122021

Categories: Literature Watch

Pharmacogenetics of <em>CYP2A6</em>, <em>CYP2B6</em>, and <em>UGT2B7</em> in the Context of HIV Treatments in African Populations

Fri, 2022-12-23 06:00

J Pers Med. 2022 Dec 5;12(12):2013. doi: 10.3390/jpm12122013.

NO ABSTRACT

PMID:36556234 | DOI:10.3390/jpm12122013

Categories: Literature Watch

Genetic Biomarkers of Antipsychotic-Induced Prolongation of the QT Interval in Patients with Schizophrenia

Fri, 2022-12-23 06:00

Int J Mol Sci. 2022 Dec 13;23(24):15786. doi: 10.3390/ijms232415786.

NO ABSTRACT

PMID:36555428 | DOI:10.3390/ijms232415786

Categories: Literature Watch

Genetic and Epigenetic Etiology of Inflammatory Bowel Disease: An Update

Fri, 2022-12-23 06:00

Genes (Basel). 2022 Dec 16;13(12):2388. doi: 10.3390/genes13122388.

NO ABSTRACT

PMID:36553655 | DOI:10.3390/genes13122388

Categories: Literature Watch

Converging Evidence Points to BDNF as Biomarker of Depressive Symptoms in Schizophrenia-Spectrum Disorders

Fri, 2022-12-23 06:00

Brain Sci. 2022 Dec 4;12(12):1666. doi: 10.3390/brainsci12121666.

NO ABSTRACT

PMID:36552127 | DOI:10.3390/brainsci12121666

Categories: Literature Watch

Pages